Zoledronic acid, or zoledronate, is a nitrogen-containing bisphosphonate widely used to treat osteoporosis and metastatic bone disease. It inhibits osteoclast function by binding to hydroxyapatite, reducing bone resorption and increasing bone mineral density. Despite its proven efficacy in increasing bone mineral density and reducing the incidence of fractures, adverse effects have been documented, including ocular side effects such as acute anterior uveitis. It's well known that osteoporosis primarily affects postmenopausal women and represents a significant economic burden in health care systems due to continued fragility fractures. In this case series, we present two cases of postmenopausal women who have been diagnosed with severe osteoporosis. The first case is a 71-year-old woman with a history of rheumatoid arthritis, and the second is a 67-year-old patient with a history of congenital hip dysplasia. Both patients received IV zoledronic acid for osteoporosis treatment. Within a few days after infusion, both developed symptoms consistent with